[go: up one dir, main page]

ATE419863T1 - Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit - Google Patents

Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit

Info

Publication number
ATE419863T1
ATE419863T1 AT02768992T AT02768992T ATE419863T1 AT E419863 T1 ATE419863 T1 AT E419863T1 AT 02768992 T AT02768992 T AT 02768992T AT 02768992 T AT02768992 T AT 02768992T AT E419863 T1 ATE419863 T1 AT E419863T1
Authority
AT
Austria
Prior art keywords
pyy3
reducing
preventing obesity
subject
decreasing
Prior art date
Application number
AT02768992T
Other languages
English (en)
Inventor
Michael Cowley
Roger Cone
Malcolm Low
Andrew Butler
Stephen R Bloom
Caroline J Small
Rachael L Batterham
Mohammad Ali Ghatei
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0200507.2A external-priority patent/GB0200507D0/en
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE419863T1 publication Critical patent/ATE419863T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Liquid Developers In Electrophotography (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Lasers (AREA)
  • Toilet Supplies (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Fats And Perfumes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT02768992T 2001-09-24 2002-09-24 Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit ATE419863T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32440601P 2001-09-24 2001-09-24
GBGB0200507.2A GB0200507D0 (en) 2002-01-10 2002-01-10 Appetite suppression
US39210902P 2002-06-28 2002-06-28

Publications (1)

Publication Number Publication Date
ATE419863T1 true ATE419863T1 (de) 2009-01-15

Family

ID=27256373

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02768992T ATE419863T1 (de) 2001-09-24 2002-09-24 Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit

Country Status (19)

Country Link
US (2) US7459432B2 (de)
EP (2) EP1499277B1 (de)
JP (3) JP2005508324A (de)
KR (1) KR100989647B1 (de)
CN (1) CN100350968C (de)
AT (1) ATE419863T1 (de)
AU (1) AU2002332054B2 (de)
BR (1) BR0212985A (de)
CA (1) CA2461345A1 (de)
DE (1) DE60230818D1 (de)
DK (1) DK1499277T3 (de)
ES (1) ES2320979T3 (de)
HK (1) HK1070281A1 (de)
HU (1) HU228621B1 (de)
IL (3) IL160983A0 (de)
MX (1) MXPA04002751A (de)
NZ (1) NZ532427A (de)
PL (1) PL205971B1 (de)
WO (1) WO2003026591A2 (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
JP2003518914A (ja) 1999-02-10 2003-06-17 キュリス インコーポレイテッド グルコース代謝障害を治療する方法および試薬
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
ATE450269T1 (de) 2000-12-14 2009-12-15 Amylin Pharmaceuticals Inc Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP1585956A4 (de) 2001-09-24 2009-10-21 Univ Oregon Health & Science Beurteilung von neuronen im nucleus arcuatus zum screening auf das essverhalten verändernde stoffe
MXPA04002751A (es) 2001-09-24 2005-09-08 Univ Oregon Health & Science Modificacion del comportamiento de alimentacion.
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004056314A2 (en) 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1964630A (zh) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
EP2422806A3 (de) 2004-02-11 2012-06-13 Amylin Pharmaceuticals Inc. Hybridpolypeptide mit auswahlbaren Eigenschaften
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
WO2005080424A2 (en) * 2004-02-23 2005-09-01 Rheoscience A/S Peptide yy analogues
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
GB0411014D0 (en) * 2004-05-18 2004-06-23 Haptogen Ltd Methods for the control treatment and management of obesity
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
CN105708787A (zh) * 2004-07-12 2016-06-29 爱密斯菲尔科技公司 用于递送肽yy和pyy激动剂的组合物
AU2005291359B2 (en) * 2004-10-07 2011-10-13 Nestec S.A. Bioactive compositions, natural methods of producing them and computational methods for designing natural production processes
WO2006042242A2 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them
NZ555464A (en) 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
KR101272402B1 (ko) 2004-12-13 2013-06-10 아스트라제네카 파마수티컬스 엘피 췌장 폴리펩티드 족 모티프, 폴리펩티드 및 이를 포함하는방법
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
SG159551A1 (en) 2005-02-11 2010-03-30 Amylin Pharmaceuticals Inc Gip analog and hybrid polypeptides with selectable properties
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2005337101A1 (en) * 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
BRPI0520563A2 (pt) 2005-09-21 2009-05-19 7Tm Pharma As agonistas de receptores y4 seletivos para intervenções terapêuticas
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
WO2007039318A2 (en) * 2005-10-06 2007-04-12 Bayer Schering Pharma Aktiengesellschaft Neuropeptide y analogs
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
WO2007085887A1 (en) * 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
US8977517B2 (en) * 2006-06-05 2015-03-10 Creighton University System and methods for evaluating efficacy of appetite-affecting drugs
GB0613196D0 (en) * 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314B1 (de) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US7814038B1 (en) * 2007-12-06 2010-10-12 Dominic John Repici Feedback-tolerant method and device producing weight-adjustment factors for pre-synaptic neurons in artificial neural networks
US9938333B2 (en) * 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010090876A2 (en) 2009-01-21 2010-08-12 University Of Florida Research Foundation, Inc. Satiation peptide administration
WO2011002066A1 (ja) * 2009-07-02 2011-01-06 武田薬品工業株式会社 ペプチド及びその用途
US8298561B2 (en) 2009-09-28 2012-10-30 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3326620B1 (de) 2010-12-16 2020-03-04 Novo Nordisk A/S Feste zusammensetzungen mit einem glp-1-agonisten und einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012220595B2 (en) 2011-02-25 2015-07-16 Merck Sharp & Dohme Llc Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AP2013007180A0 (en) 2011-04-25 2013-10-31 Advanced Bioscience Lab Inc Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
SMT201800491T1 (it) 2012-03-22 2018-11-09 Novo Nordisk As Composizioni di peptidi glp-1 e relativa preparazione
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
EP2958562A4 (de) 2013-02-22 2016-08-10 Merck Sharp & Dohme Antidiabetische bicyclische verbindungen
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10017554B2 (en) 2013-04-10 2018-07-10 University Of Copenhagen Neuropeptide Y-derived peptides
CA2909045C (en) * 2013-05-02 2022-12-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
ES2688462T3 (es) 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2929672A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
CN105764919B (zh) 2013-11-15 2021-04-27 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
US20170137486A1 (en) 2014-05-23 2017-05-18 Imperial Innovations Limited Peptide yy (pyy) analogues
RU2021109549A (ru) 2014-08-29 2021-05-13 Тес Фарма С.Р.Л. ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
MA43205A (fr) 2015-06-12 2018-09-19 Novo Nordisk As Composés pyy sélectifs et leurs utilisations
KR101604212B1 (ko) * 2015-07-17 2016-03-17 울산대학교 산학협력단 Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
LT3393655T (lt) 2015-12-22 2021-03-25 Zogenix International Limited Fenfluramino kompozicijos ir jų paruošimo būdai
US11311633B2 (en) 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
TWI754643B (zh) 2016-05-16 2022-02-11 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP4201427A1 (de) 2016-08-24 2023-06-28 Zogenix International Limited Formulierung zur hemmung der bildung von 5-ht2b-agonisten und verfahren zur verwendung davon
BR112019007543A2 (pt) 2016-10-14 2019-07-02 Tes Pharma S R L inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US12240890B2 (en) * 2017-05-16 2025-03-04 The University Of Chicago Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
KR20200132852A (ko) * 2018-01-23 2020-11-25 길라 테라퓨틱스, 인코포레이티드 펩티드 yy 약학적 제형, 조성물, 및 방법
MA53076B1 (fr) 2018-02-02 2023-11-30 Novo Nordisk As Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
EP3790537A1 (de) 2018-05-11 2021-03-17 Zogenix International Limited Zusammensetzungen und verfahren zur behandlung von plötzlichem tod infolge eines krampfanfalls
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN113092427A (zh) * 2021-04-02 2021-07-09 南京中医药大学 异硫氰酸荧光素在标记β内啡肽中的应用

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4223017A (en) 1975-04-15 1980-09-16 Burroughs Wellcome Co. Biologically active amides
GB1560933A (en) 1975-04-15 1980-02-13 Wellcome Found Biologically activy polypeptides
US4175122A (en) 1975-04-15 1979-11-20 Burroughs Wellcome Co. Biologically active amides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4220653A (en) * 1979-01-24 1980-09-02 Vivino A Earl Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4229389A (en) 1979-03-16 1980-10-21 Thompson Marine Corporation Gas diffuser, aerator, or sparger apparatus
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0142641B1 (de) * 1983-09-26 1991-01-16 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (de) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
US4701441A (en) 1985-02-11 1987-10-20 University Of Florida Methods and compositions for stimulation of appetite
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
HU196755B (en) 1986-09-16 1989-01-30 Gyogyszerkutato Intezet Process for production of new substituated amilid derivatives and medical compositions containing them
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
AU633011B2 (en) 1988-06-28 1993-01-21 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0401384B1 (de) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemisch modifizierte granulocytenkolonie erregender faktor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE9002278L (sv) 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2123108C (en) 1991-11-06 2003-03-25 Lisa Selbie Human neuropeptide y-y1 receptor
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
WO1994010220A1 (en) 1992-10-28 1994-05-11 Kuraray Co., Ltd. Polyurethane and leatherlike sheet made therefrom
JP2961045B2 (ja) * 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
CA2204645A1 (en) 1994-11-07 1996-05-17 Keiichi Yano Novel oxyntomodulin
EP0791009A4 (de) 1994-11-07 2003-03-05 Merck & Co Inc Modifizierter neuropeptid-y-rezeptor
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5912227A (en) * 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5668151A (en) 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
DK1238659T3 (da) 1996-02-02 2005-01-24 Alza Corp Vedvarende frigivelse af et aktivt middel ved anvendelse af et implanterbart system
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US5919901A (en) 1996-04-08 1999-07-06 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ES2290799T3 (es) 1996-11-12 2008-02-16 Novo Nordisk A/S Uso de peptidos glp-1.
JP2000505105A (ja) 1996-11-13 2000-04-25 ユニヴァーシティ・オブ・シンシナティ ペプチドｙｙのアナログおよびその使用
PT1629849E (pt) * 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
US5889016A (en) 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
EP0920864A1 (de) 1997-12-03 1999-06-09 Pfizer Products Inc. Kombinationstherapie durch einen spezifischen beta-3 Agonisten und einen Appetithemmer
EP2574336A1 (de) * 1998-02-02 2013-04-03 Trustees Of Tufts College Verwendung von Dipeptidylpeptidaseinhibitoren zur Regulierung des Glucosemetabolismus
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
ATE269846T1 (de) 1998-04-29 2004-07-15 Ortho Mcneil Pharm Inc N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
CN1329589A (zh) 1998-10-07 2002-01-02 奥索-麦克尼尔药品公司 用作神经肽yy5受体的配体的n－芳烷基氨基1,2,3,4－四氢萘
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
EP1147094A1 (de) 1999-01-15 2001-10-24 Novo Nordisk A/S Nicht-peptidische glp-1 agonisten
JP2003518914A (ja) 1999-02-10 2003-06-17 キュリス インコーポレイテッド グルコース代謝障害を治療する方法および試薬
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
WO2000059887A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
CA2373035A1 (en) 1999-05-05 2000-11-16 Scott Dax 3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
PT1133312E (pt) 1999-06-21 2007-11-30 Lilly Co Eli Uso sinergístico de tiazolidinodionas com péptido 1 semelhante ao glucagon e os seus agonistas para tratar diabetes não insulino-dependente
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
EP1076066A1 (de) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptide zur Senkung des Blutglukosespiegels
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
NZ516782A (en) 1999-07-28 2004-12-24 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
CA2382528A1 (en) * 1999-08-25 2001-03-01 Banyu Pharmaceutical Co., Ltd. Novel isoindole derivatives
CA2381111A1 (en) 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
AU6798000A (en) 1999-08-26 2001-03-19 Viropharma Incorporated Compounds, compositions and methods for treating influenza
YU23802A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini
EP1239871A1 (de) 1999-11-12 2002-09-18 Novo Nordisk A/S Verwendung von glp-1-agonisten zur hemmung der degeneration von beta-zellen
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6699891B1 (en) * 1999-11-26 2004-03-02 Shionogi & Co., Ltd. Npyy5 antagonists
EP1246638B2 (de) 2000-01-10 2014-07-30 Amylin Pharmaceuticals, Inc. Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
EP1263458B1 (de) 2000-03-08 2005-11-16 Novo Nordisk A/S Senkung des serum cholesterols
WO2001068699A2 (en) 2000-03-16 2001-09-20 Bayer Aktiengesellschaft Regulation of human neuropeptide y-like g protein-coupled receptor
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
EP1286697A2 (de) 2000-05-17 2003-03-05 Eli Lilly And Company Methode zur selektiven hemmung der aktivität von ghrelin
US6256216B1 (en) * 2000-05-18 2001-07-03 Integrated Device Technology, Inc. Cam array with minimum cell size
WO2001089554A2 (en) 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
IL153513A0 (en) 2000-07-06 2003-07-06 Metabasis Therapeutics Inc A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US20020156010A1 (en) * 2000-11-20 2002-10-24 Lustig Robert H. Method of treating obesity in adult patients exhibiting primary insulin hypersecretion
ATE450269T1 (de) * 2000-12-14 2009-12-15 Amylin Pharmaceuticals Inc Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
WO2002066479A1 (fr) 2001-02-23 2002-08-29 Banyu Pharmaceutical Co.,Ltd. Derives de l'isoindole
WO2002067918A1 (fr) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Nouveau derive de diallylmethylamine
AU2002355286B2 (en) * 2001-07-26 2005-10-13 Schering Corporation Substituted urea neuropeptide Y Y5 receptor antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
MXPA04002751A (es) 2001-09-24 2005-09-08 Univ Oregon Health & Science Modificacion del comportamiento de alimentacion.
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1474163A2 (de) 2002-01-10 2004-11-10 Imperial College Innovations Limited Veränderung des fütterungsverhaltens
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
CN1220702C (zh) 2003-07-30 2005-09-28 北京中科亚光生物科技有限公司 促胰岛素分泌肽及其用途
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
EP2740743A3 (de) 2004-06-01 2015-08-19 Domantis Limited Bispezifische Fusions-Antikörper mit erhöhter Serumhalbwärtszeit
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2008543816A (ja) 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド 新規化合物および該化合物が摂食行動に及ぼす効果
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響

Also Published As

Publication number Publication date
US20090209461A1 (en) 2009-08-20
HK1070281A1 (en) 2005-06-17
EP1499277B1 (de) 2009-01-07
HUP0600337A3 (en) 2011-03-28
WO2003026591A3 (en) 2004-10-28
PL374270A1 (en) 2005-10-03
CA2461345A1 (en) 2003-04-03
HU228621B1 (en) 2013-04-29
WO2003026591A9 (en) 2004-07-08
US20050176630A1 (en) 2005-08-11
EP1499277A2 (de) 2005-01-26
IL199364A (en) 2012-02-29
MXPA04002751A (es) 2005-09-08
IL199364A0 (en) 2011-07-31
AU2002332054B2 (en) 2007-11-08
KR100989647B1 (ko) 2010-10-26
JP2010111694A (ja) 2010-05-20
JP6124565B2 (ja) 2017-05-10
CN1596119A (zh) 2005-03-16
JP2005508324A (ja) 2005-03-31
US8217001B2 (en) 2012-07-10
HUP0600337A2 (en) 2006-08-28
US7459432B2 (en) 2008-12-02
EP1499277A4 (de) 2005-08-31
EP2050460A1 (de) 2009-04-22
CN100350968C (zh) 2007-11-28
KR20090122497A (ko) 2009-11-30
IL160983A (en) 2010-11-30
IL160983A0 (en) 2004-08-31
BR0212985A (pt) 2005-08-30
JP2013047275A (ja) 2013-03-07
NZ532427A (en) 2008-07-31
ES2320979T3 (es) 2009-06-01
WO2003026591A2 (en) 2003-04-03
DK1499277T3 (da) 2009-05-11
PL205971B1 (pl) 2010-06-30
DE60230818D1 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
ATE419863T1 (de) Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
WO2003057235A3 (en) Modification of feeding behavior
DE60140693D1 (en) Ankheiten
IL176758A0 (en) 1,3-dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes
ATE427724T1 (de) Systeme zum verschieben und/oder zuruckhalten von gewebe in den oberen atemwegen
HRP20041180A2 (en) 11-beta-hidroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
ITMI20042132A1 (it) Dispositivo e metodo per la terapia dell'obesita'
ITMI20042131A1 (it) Dispositivo e metodo per la terapia dell'obesita'
MA23533A1 (fr) Formes posologiques d'azithromycine
EP1539153A4 (de) Therapeutische behandlung des metabolischen syndroms und für diabetes typ 2
ZA200500719B (en) The use of the combination of ciclesonide and antihitamines for the treatment of allergic rhinitis.
AU2003272608A8 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
MY122838A (en) Treating allergic and inflammatory conditions
AU2003218462A8 (en) Treatment of obesity and other disorders associated with excessive food intake
SI1569634T1 (sl) Uporaba PPAR-alfa agonista in metformina za zdravljenje obezitete
ITRM20030485A0 (it) Composizione a base di citicolina in associazione con vitamine per laprevenzione ed il trattamento di patolgie oculari.
AU2003214667A1 (en) Elastic ruler for herb therapy and the therapy method for disease using the same
NZ516651A (en) 17-beta-decanoate-4estrene-3-one and 17-beta-cyclohexylpropionate-4-estrene-3-one for treating aggression and stimulating appetite in stags (deer) during puberty especially for promoting and obtaining stag's horn
TW200833336A (en) Method of treatment of obesity
AU2003265809A1 (en) Method to treat laminitis and reduce dietary intake for horses
EP1487427A4 (de) Verfahren zur prävention und behandlung von peripherer neuropathie durch verabreichung von desmethylselegilin
BR9301908A (pt) Aparelho contra apneia e ronco
ITRM20020132U1 (it) Lettino terapeutico "modesti" in legno naturale non trattato con cristalli o pietre incastonati.
ITRM20020380A1 (it) Lettino terapeutico 'modesti' in legno naturale non trattato con cristalli o pietre incastonati.
GB0212031D0 (en) IL-11 Derivatives and therapeutical uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties